Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Gainers
Cochlear (ASX:COH) share price charges higher on AGM update
Broker Notes
Could the Cochlear (ASX:COH) share price hit $260 by the end of 2021?
Share Market News
Top broker sees 19% upside in the Cochlear (ASX:COH) share price
Growth Shares
Analysts name 3 stellar ASX growth shares to buy
Broker Notes
Leading brokers name 3 ASX shares to sell today
Share Fallers
Why APN Industria, Centuria Industrial, Cochlear, & Perseus Mining are tumbling
Share Market News
Which ASX 300 shares are the major movers at the end of the week?
Share Market News
ASX 200 (ASX:XJO) midday update: Telstra buys Vita stores, Cochlear sinks
Share Fallers
Cochlear (ASX:COH) share price down 4% on US patent infringement complaint
Dividend Investing
4 ASX shares going ex-dividend today
Healthcare Shares
Why has the Cochlear (ASX:COH) share price been struggling lately?
Dividend Investing
These 5 ASX 200 shares are going ex-dividend this week
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
